APA (7th ed.) Citation

Fink, W., Figl, A., Figl, R., Ugurel, S., & Schadendorf, D. (2004). Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie, 27(6), . https://doi.org/10.1159/000081335

Chicago Style (17th ed.) Citation

Fink, Wolfram, Adina Figl, Robert Figl, Selma Ugurel, and Dirk Schadendorf. "Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-line Treatment in Disseminated Melanoma." Onkologie 27, no. 6 (2004). https://doi.org/10.1159/000081335.

MLA (9th ed.) Citation

Fink, Wolfram, et al. "Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-line Treatment in Disseminated Melanoma." Onkologie, vol. 27, no. 6, 2004, https://doi.org/10.1159/000081335.